LCM
ELVN icon

Legato Capital Management’s Enliven Therapeutics ELVN Stock Holding History

Legato Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.29M Buy
64,769
+33,595
+108% +$1.43M 0.27% 108
2026
Q1 		$1.22M Buy
+31,174
New +$864K 0.11% 242
2025
Q1 		– Sell
-13,492
Closed -$304K – 590
2024
Q4 		$304K Sell
13,492
-1,090
-7% -$28.3K 0.04% 495
2024
Q3 		$372K Buy
+14,582
New +$338K 0.05% 479

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Legato Capital Management's ELVN Position: Q2 2026 in Review

Legato Capital Management increased its Enliven Therapeutics (ELVN) stake by 108% in Q2 2026, buying an estimated $1.43M and bringing the position to 64,769 shares worth $3.29M. The position accounts for 0.27% of the portfolio, ranked #108.

Legato Capital Management first reported a position in ELVN in Q3 2024 and has held it in 4 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Legato Capital Management held 64,769 shares of Enliven Therapeutics worth $3.29M as of Q2 2026.
  • Legato Capital Management bought 33,595 Enliven Therapeutics shares in Q2 2026, an estimated $1.43M.
  • Enliven Therapeutics made up 0.27% of Legato Capital Management's portfolio in Q2 2026, its #108 holding.
  • Legato Capital Management first reported a position in Enliven Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.